Physician profile
Darian Eugene Reddick
NPI 1497044093
$7,348.81
in general payments reported to CMS, 2019-2025
22 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,004 · 2020: $156 · 2021: $305 · 2022: $328 · 2023: $372 · 2024: $984 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,402 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.57 |
| Education | $154.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $4,579.99 | 2019-2024 | Hizentra |
| Abbvie INC. | $732.04 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $602.72 | 2019-2023 | |
| Pfizer INC. | $328.28 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $203.05 | 2021-2024 | |
| Sk Life Science, INC. | $124.97 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $116.91 | 2023-2024 | Austedo Xr |
| Acadia Pharmaceuticals INC | $100.32 | 2024-2025 | Nuplazid |
| Janssen Biotech, INC. | $99.99 | 2025 | |
| Ucb, INC. | $78.59 | 2024 | Nayzilam, Rystiggo |
| Alnylam Pharmaceuticals INC. | $62.83 | 2024 | Onpattro |
| Alexion Pharmaceuticals, INC. | $49.49 | 2022-2024 | Ultomiris |
| Eisai INC. | $40.92 | 2024 | |
| Amgen INC. | $37.55 | 2022-2024 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $30.17 | 2024 | Hyqvia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $29.59 | 2019 | |
| Axsome Therapeutics, INC. | $29.00 | 2025 | Symbravo |
| Otsuka America Pharmaceutical, INC. | $28.74 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $24.52 | 2024 | Arexvy, Trelegy Ellipta |
| Hologic Sales and Service, LLC | $23.00 | 2023 | Aptima |
| Tanabe Pharma America, INC. | $17.56 | 2024 | |
| Sumitomo Pharma America, INC. | $8.58 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darian Reddick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.